Cardiovascular disease reduction in the outpatient kidney transplant clinic

Area of Science:

• Nephrology
• Cardiology
• Transplantation Medicine

Background:

• Cardiovascular disease (CVD) is a leading cause of death in kidney transplant recipients.
• Risk stratification and management are crucial for improving outcomes in this vulnerable population.

Purpose of the Study:

• To estimate future CVD mortality in kidney transplant recipients.
• To compare current, optimal, and historic CVD mortality rates.
• To identify barriers to achieving optimal CVD risk reduction.

Main Methods:

• A risk calculator was used to estimate CVD mortality in 439 kidney transplant recipients.
• Three scenarios were calculated: CURRENT (observed rates), OPTIMAL (with enhanced therapy), and HISTORIC (based on past practices).
• Medication adherence and contraindications were assessed.

Main Results:

• Predicted CURRENT CVD mortality is 82% of HISTORIC rates.
• Predicted OPTIMAL CVD mortality is 90% of CURRENT rates, requiring a 27% increase in antihypertensive and lipid-lowering drug use.
• Physician prescribing appears to be a major barrier to optimal therapy.
• Even with OPTIMAL rates, transplant recipients have 2.3 times higher relative CVD risk than the general population.

Conclusions:

• Targeted CVD risk reduction therapies offer substantial benefits for kidney transplant recipients.
• Despite improvements, CVD mortality risk remains significantly higher than in the general population.
• Addressing physician prescribing patterns is key to minimizing CVD risk in this cohort.